[1] GBD 2019, Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Gastroenterol Hepatol, 2022, 7(7):627-647. [2] ZHANG S Z, ZHANG L, XIE L. Cancer burden in China during 1990-2019:analysis of the global burden of disease[J]. Biomed Res Int, 2022, 2022:3918045. [3] BOSMAN F T. WHO classification of tumours of the digestive system[M]. 4th ed. Lyon:International Agency for Research on Cancer, 2010:1089. [4] SHAUKAT A, KAHI C J, BURKE C A, et al. ACG clinical guidelines:colorectal cancer screening 2021[J]. Am J Gastroenterol, 2021, 116(3):458-479. [5] TEMPLETON A J, ACE O, MCNAMARA M G, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors:a systematic review and Meta-analysis[J]. Cancer Epidemiol Biomark Prev, 2014, 23(7):1204-1212. [6] HE X S, WU K N, OGINO S, et al. Association between risk factors for colorectal cancer and risk of serrated polyps and conventional adenomas[J]. Gastroenterology, 2018, 155(2):355-373. [7] BJERRUM A, LINDEBJERG J, ANDERSEN O, et al. Long-term risk of colorectal cancer after screen-detected adenoma:experiences from a Danish gFOBT-positive screening cohort[J]. Int J Cancer, 2020, 147(4):940-947. [8] AHNEN D J. The American College of Gastroenterology Emily Couric Lecture:the adenoma-carcinoma sequence revisited:has the era of genetic tailoring finally arrived-[J]. Am J Gastroenterol, 2011, 106(2):190-198. [9] CHEN R, WANG L G, ZHAO Q, et al. Platelet-to-lymphocyte ratio and C-reactive protein as markers for colorectal polyp histological type[J]. BMC Cancer, 2021, 21(1):556. [10] DUBÉ C, YAKUBU M, MCCURDY B R, et al. Risk of advanced adenoma, colorectal cancer, and colorectal cancer mortality in people with low-risk adenomas at baseline colonoscopy:a systematic review and Meta-analysis[J]. Am J Gastroenterol, 2017, 112(12):1790-1801. [11] 房静远, 李延青, 陈萦晅, 等. 中国结直肠肿瘤综合预防共识意见(2021年, 上海)[J]. 胃肠病学, 2021, 26(5):279-311. [12] OSTAN R, LANZARINI C, PINI E, et al. Inflammaging and cancer:a challenge for the Mediterranean diet[J]. Nutrients, 2015, 7(4):2589-2621. [13] 张宁. 临床血液学参数与宫颈癌前病变及宫颈癌的关系研究[D]. 济宁:济宁医学院, 2021. [14] WANG B L, HUANG Y, LIN T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma:a meta-analysis[J]. Medicine, 2020, 99(1):e18571. [15] WANG Y, LI Y N, CHEN P R, et al. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer:a meta-analysis[J]. Ann Transl Med, 2019, 7(18):433. [16] DONG M L, SHI Y G, YANG J, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer:a meta-analysis[J]. Ther Adv Med Oncol, 2020, 12:1758835920937425. [17] QIU Y, ZHANG Z X, CHEN Y. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer:a Meta-analysis[J]. Front Oncol, 2021, 11:537140. [18] MOSES K, BRANDAU S. Human neutrophils:their role in cancer and relation to myeloid-derived suppressor cells[J]. Semin Immunol, 2016, 28(2):187-196. [19] FELIX K, GAIDA M M. Neutrophil-derived proteases in the microenvironment of pancreatic cancer-active players in tumor progression[J]. Int J Biol Sci, 2016, 12(3):302-313. [20] ORELLANA R, KATO S, ERICES R, et al. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells[J]. BMC Cancer, 2015, 15:290. [21] COUPLAND L A, PARISH C R. Platelets, selectins, and the control of tumor metastasis[J]. Semin Oncol, 2014, 41(3):422-434. [22] QUIGLEY D A, KRISTENSEN V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells[J]. Mol Oncol, 2015, 9(10):2054-2062. |